Safety and Efficacy Study Using Gene Therapy for Critical Limb Ischemia
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 200 participants.
Also called NCT01548378
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 200 participants
- Registry
-
NCT01548378
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT01548378. Randomized; quadruple masking; primary purpose treatment. Start 2012-03 (registry gives no type); primary completion 2014-06 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Safety and Efficacy Study Using Gene Therapy for Critical Limb Ischemia
- Acronym
- NL003CLI-II
- Condition
- Arterial Occlusive Disease
- Condition
- Ulcers
- Condition
- Ischemia
- Condition
- Peripheral Vascular Disease
- Intervention (Genetic)
- NL003
- Intervention (Genetic)
- NL003
- Intervention (Genetic)
- NL003
- Intervention (Other)
- Normal Saline
- Lead sponsor
- Beijing Northland Biotech. Co., Ltd.
Record details
- Record id
cardio:ct-nct01548378- Content hash
4617e27a2340ef2a43a0985ae72f90bce8874dcea01bd3c8dee246363acfa041